title: A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study.
abstract: The NCI Canada Clinical Trials Group conducted a phase II study of menogaril given intravenously every 4 weeks in low-grade non-Hodgkin's lymphoma. Fifteen of 26 eligible patients had had no prior therapy. Partial responses were seen in 9 patients (35%). Toxicity was moderate including myelosuppression, nausea, phlebitis, alopecia, and lethargy. This drug has only modest activity in this potentially responsive group of patients.
authors.affiliation: London Regional Cancer Centre, Ontario, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Skillings
authors.forename: C
authors.initials: C
authors.lastname: Cripps
authors.forename: E
authors.initials: E
authors.lastname: Eisenhauer
authors.forename: J
authors.initials: J
authors.lastname: Pater
authors.forename: S
authors.initials: S
authors.lastname: Verma
authors.forename: D
authors.initials: D
authors.lastname: Walde
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D007275:Injections, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D017290:Menogaril; D008875:Middle Aged; D009621:Nogalamycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D017290:Menogaril; D009621:Nogalamycin